Adaptimmune Therapeutics PLC
ADAPY · OTCMCIK 1621227fmd_0GFD7D0NMYM8N8G0RKPRCM52T6Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jul 01, 2012 to Jun 30, 2025, 44 periods
Loading
Latest annual · FY2024
Millions- Total revenues
- 178
- Gross profit
- 178
- Operating income
- (69)
- Net income
- (71)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- +207.1%
- Revenue, 5 yearsFY2019 to FY2024
- +175.5%
- Net income, 5 yearsFY2019 to FY2024
- n/m
Adaptimmune Therapeutics PLC (ADAPY) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $178 million | $60.3 million | +195.3% | 10-K 2025-03-24 · proof |
| Gross profit | $178 million | 10-K 2025-03-24 · proof | ||
| Operating income | -$68.8 million | -$139.7 million | 10-K 2025-03-24 · proof | |
| Net income | -$70.8 million | -$113.9 million | 10-K 2025-03-24 · proof | |
| Cash from operating activities | -$73.2 million | -$140.9 million | 10-K 2025-03-24 · proof | |
| Free cash flow | -$74.1 million | -$145.6 million | 10-K 2025-03-24 · proof |
- What was Adaptimmune Therapeutics PLC (ADAPY)'s revenue in fiscal 2024?
- Adaptimmune Therapeutics PLC (ADAPY) reported revenue of $178 million for fiscal 2024 (the year ended Dec 31, 2024), against $60.3 million the year before (+195.3%). Source: the 10-K filed with the SEC on Mar 24, 2025. SEC
- What was Adaptimmune Therapeutics PLC (ADAPY)'s gross profit in fiscal 2024?
- Adaptimmune Therapeutics PLC (ADAPY) reported gross profit of $178 million for fiscal 2024 (the year ended Dec 31, 2024). Source: the 10-K filed with the SEC on Mar 24, 2025. SEC
- What was Adaptimmune Therapeutics PLC (ADAPY)'s operating income in fiscal 2024?
- Adaptimmune Therapeutics PLC (ADAPY) reported operating income of -$68.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$139.7 million the year before. Source: the 10-K filed with the SEC on Mar 24, 2025. SEC
- What was Adaptimmune Therapeutics PLC (ADAPY)'s net income in fiscal 2024?
- Adaptimmune Therapeutics PLC (ADAPY) reported net income of -$70.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$113.9 million the year before. Source: the 10-K filed with the SEC on Mar 24, 2025. SEC
- What was Adaptimmune Therapeutics PLC (ADAPY)'s cash from operating activities in fiscal 2024?
- Adaptimmune Therapeutics PLC (ADAPY) reported cash from operating activities of -$73.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$140.9 million the year before. Source: the 10-K filed with the SEC on Mar 24, 2025. SEC
- What was Adaptimmune Therapeutics PLC (ADAPY)'s free cash flow in fiscal 2024?
- Adaptimmune Therapeutics PLC (ADAPY) reported free cash flow of -$74.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$145.6 million the year before. Source: the 10-K filed with the SEC on Mar 24, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ADAPY&period_type=annual&limit=5"Information only, not investment advice.